HUMAN CAPITAL PULSE: LIFE SCIENCES · ISSUE 8 · AUGUST 2026
A monthly Human Capital benchmark for HR and People leaders in Life Sciences: the sector's talking points and how culture, workforce and talent compare across your peers, built on Deltabase data covering 5,500+ companies and 11M employee reviews.
August brought mixed signals. Pfizer added $2.5 billion to its cost-cutting programme and Sanofi closed former Blueprint Medicines offices in Cambridge, Massachusetts, yet BioSpace reported job postings rising for a third straight quarter. As employers consolidate sites and candidates regain some leverage, flexibility and the way managers lead dispersed teams matter more. This issue looks at both.
Leroy Hall, Deltabase
What happened: Pfizer said alongside its second-quarter results that it will find an additional $2.5 billion of cost savings between 2027 and 2029, taking its three-year target above $10 billion, pharmaphorum reported on 4 August. The new cuts focus on manufacturing network changes and operational efficiencies, after headcount fell by about 13,000 across 2024 and 2025 to roughly 75,000.
The Deltabase lens: Employees already feel the weight of process. Pfizer's Agility & Bureaucracy score fell to −67.7% in 2025 from −60.4% in 2024 in Deltabase Culture data.
So what: Efficiency programmes that add approvals and handoffs can undo themselves. Ask employees which processes slow them down before deciding what to cut.
What happened: BioSpace's Q2 job market report, published on 7 August, showed live postings up 15% year on year and 12% on the quarter, the third consecutive quarterly rise. Biotech R&D postings were up 42% year on year in June, applications per posting fell from about 5 to 4.4, and 26 companies cut staff in Q2 against 64 a year earlier.
The Deltabase lens: Digital roles are often the easiest to offer flexibly, and their weight differs by employer. Tech makes up 9.4% of Eli Lilly's workforce in Deltabase Workforce data, against 8.7% at AstraZeneca, 8.2% at Novartis, 7.2% at GSK and 6.6% at AbbVie.
So what: Fewer applicants per role means flexibility becomes a bargaining chip again. Be clear which roles can be hybrid, and why.
What happened: Sanofi is laying off 229 former Blueprint Medicines employees in Cambridge, Massachusetts, and closing two legacy Blueprint buildings, with remaining staff moving to Sanofi's East Cambridge office, pharmaphorum reported on 17 August. All 13 members of Blueprint's listed leadership team have left in the year since the roughly $9 billion acquisition closed.
The Deltabase lens: Sanofi's culture is strong overall, but employees feel less empowered: its Empowered score fell to −20.9% in 2025 from +12.5% in 2024. Deltabase Talent data shows 4.8% of Sanofi's workforce hold change management skills.
So what: Moving acquired teams into a parent's office is a culture change as much as a property one. Give integrated teams a say in how they work, not just where.
−38.4%: Eli Lilly's Supportive Leadership score in 2025, the weakest of these five peers; four of the five sit below −25%
| Company | Supportive Leadership NSS 2025 | Supportive Leadership NSS 2024 | Workforce with digital transformation skills |
|---|---|---|---|
| Eli Lilly | −38.4% | −34.2% | 1.8% |
| Bristol Myers Squibb | −36.2% | −32.0% | 1.6% |
| AbbVie | −28.4% | −27.6% | 1.1% |
| Boehringer Ingelheim | −27.4% | −28.6% | 1.6% |
| Sanofi | −8.6% | −14.9% | 2.2% |
Source: Deltabase Culture data, Supportive Leadership topic, Employee Net Sentiment Score (−100% to +100%), 2024–2025; Deltabase Talent data, share of workforce holding digital transformation skills.
Bristol Myers Squibb employees are far more positive about work-life balance: its Work-Life Balance score was +29.7% in 2025, against +1.8% at AbbVie. Overall sentiment moved the other way, with AbbVie up to +6.6% (+2.0 pts) and BMS down to +3.1% (−3.4 pts), the lowest in our ten-company peer set. Both invest heavily in learning, with L&D skills held by 24.3% of AbbVie's workforce and 22.8% of BMS's, while BMS has slightly more machine learning depth (2.9% against 2.1%). AbbVie's workforce leans to research, with 17.5% in R&D in Deltabase Workforce data.
See how your Human Capital compares with your Life Sciences peers. Book a 30-minute benchmark walkthrough across culture, workforce and talent. Book a walkthrough →
Sources: pharmaphorum (4 August 2026); BioSpace (7 August 2026); pharmaphorum (17 August 2026); Deltabase Culture data; Deltabase Workforce data; Deltabase Talent data.